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Introduction
Fanconi anemia (FA) is a human genetic disorder characterized by 
congenital abnormalities, bone marrow failure, chromosomal in-
stability, cancer susceptibility, and a profound sensitivity to agents 
that produce interstrand DNA cross-links (ICLs). To date, 13 FA 
genetic complementation groups have been identified (Moldovan 
and D’Andrea, 2009). Consistent with the sensitivity to ICLs, the 
proteins encoded by the FANC genes repair these lesions. Although 
the molecular and biochemical functions of the FA pathway remain 
poorly understood, the following model has emerged. In response 
to ICLs and replication stress, FANCM and FAAP24 are recruited 
to replication forks stalled either by ICLs or other forms of replica-
tion stress (Ciccia et al., 2007; Kim et al., 2008). The FANCM–
FAAP24 complex promotes chromatin loading of the FA core 
complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL,  and  FAAP100),  which  contains  FA  complementation 
group L (FANCL) protein, an E3 ubiquitin ligase. FANCL and 
UBE2T, its partner E2 ubiquitin–conjugating enzyme, catalyze the 
monoubiquitylation of both FA complementation group I (FANCI) 
and FANCD2, which form the FANCI–FANCD2 (ID) complex. 
Ubiquitylation of the ID complex targets it to the stalled replica-
tion fork or site of damage, where it promotes processing and   
repair of the ICL lesion (Räschle et al., 2008; Knipscheer et al., 
2009; Kratz et al., 2010; Smogorzewska et al., 2010).
ICLs and other forms of replication stress also activate the 
translesion synthesis (TLS) pathway (Lee and Myung, 2008), which 
is initiated by the recruitment of the RAD18–RAD6 complex, 
an E3 ubiquitin ligase and an E2 ubiquitin–conjugating enzyme 
pair. The RAD18–RAD6 complex ubiquitylates proliferating cell   
nuclear antigen (PCNA), a homotrimeric sliding clamp complex, 
on Lys164. PCNA ubiquitylation has a known role in the recruit-
ment and regulation of TLS polymerases, which, because of large 
active sites, have reduced fidelity but increased ability to synthe-
size over lesions that stall the high fidelity DNA polymerases (Guo   
et al., 2009). Genetic data demonstrate that RAD18 and PCNA 
ubiquitylation also play critical roles in cells challenged with agents 
that induce ICLs (Yamashita et al., 2002; Tateishi et al., 2003;   
Nojima et al., 2005; Arakawa et al., 2006; Shen et al., 2006;   
Simpson et al., 2006; Saberi et al., 2007). However, these roles   
remain poorly understood. One function for ubiquitylated PCNA 
in the repair of ICLs is to recruit or regulate the TLS DNA poly-
merases REV1 and polymerase , which are required for ICL   
repair (Sarkar et al., 2006; Shen et al., 2006). Nevertheless, PCNA 
ubiquitylation may have a previously unknown function in the 
regulation of the FA pathway. Consistent with this later possibil-
ity, we report in this study that RAD18-mediated PCNA ubiquity-
lation plays a pivotal role in FA pathway activation by regulating 
FANCL-mediated ubiquitylation of the ID complex.
T
he Fanconi anemia (FA) network is important for the 
repair of interstrand DNA cross-links. A key event in 
FA pathway activation is the monoubiquitylation of 
the FA complementation group I (FANCI)–FANCD2 (ID) 
complex by FA complementation group L (FANCL), an E3   
ubiquitin ligase. In this study, we show that RAD18,   
another DNA damage–activated E3 ubiquitin ligase, also 
participates in ID complex activation by ubiquitylating 
proliferating cell nuclear antigen (PCNA) on Lys164, an 
event required for the recruitment of FANCL to chromatin. 
We also found that monoubiquitylated PCNA stimulates 
FANCL-catalyzed  FANCD2  and  FANCI  monoubiquity-
lation.  Collectively,  these  experiments  identify  RAD18-
mediated PCNA monoubiquitination as a central hub for 
the mobilization of the FA pathway by promoting FANCL- 
mediated FANCD2 monoubiquitylation.
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FANCD2 monoubiquitylation. Basal and induced FANCD2 
monoubiquitylation was dramatically and similarly disrupted 
in cells individually depleted of FANCL or RAD18 (Fig. 2 A). 
Notably, the codepletion of FANCL and RAD18 did not further 
reduce FANCD2 monoubiquitylation. Additionally, FANCL 
depletion did not diminish PCNA monoubiquitylation (Fig. S1 F), 
thus  demonstrating  that  FANCL  does  not  participate  in  this 
PCNA modification. Consistent with the effects of these deple-
tions on FANCD2 monoubiquitylation, cells depleted of RAD18 
alone, FANCL alone, or both had nearly identical sensitivities to 
cisplatin (Fig. 2 B and Fig. S2 A [Western blot]). Collectively, 
these results suggest that RAD18 and FANCL may function in 
a common pathway in human cells.
FANCD2 ubiquitination requires  
RAD18-mediated ubiquitination of  
PCNA on Lys164
The only known RAD18 substrate is PCNA, which is ubiquity-
lated by RAD18–RAD6 on Lys164. We therefore asked whether 
PCNA ubiquitination is required for cisplatin-induced FANCD2 
monoubiquitylation  by  modifying  a  previously  described  ap-
proach (Niimi et al., 2008). Cells were transfected with an siRNA 
that depletes endogenous PCNA along with plasmids that express 
siRNA-resistant wild-type PCNA (PCNA
WT) or PCNA mutated 
at the ubiquitin acceptor site Lys164 (PCNA
K164R). The depletion 
of endogenous PCNA was highly effective (Fig. 2 C), and the 
transiently expressed S-tagged PCNA (S-PCNA) was expressed 
at levels comparable with endogenous protein. Importantly, both 
wild-type S-PCNA and S-PCNA
K164R had cycle profiles identical 
to cells cotransfected with empty vector and the luciferase control 
siRNA (Fig. S2 B), thus demonstrating that these PCNAs rescued 
replication. Analysis of these cells revealed that basal and cisplatin- 
induced  FANCD2  monoubiquitylation  was  severely  impaired 
in cells expressing PCNA
K164R compared with cells expressing 
wild-type PCNA or control cells transfected with empty vec-
tor and luciferase siRNA (Fig. 2 C). Moreover, the depletion of 
FANCD2 did not further sensitize cells expressing PCNA
K164R to 
cisplatin (Fig. S2 C). Collectively, these results show that RAD18 
regulates FANCD2 ubiquitylation through the ubiquitylation of 
PCNA on Lys164.
The FANCL and FA core complex interacts 
with PCNA
One possible way for PCNA to participate in FANCD2 ubiqui-
tination would be for PCNA to recruit FANCL to sites of DNA 
damage. Indeed, PCNA immunoprecipitates contained FANCL 
(Fig. 3 A) and the FA core complex members FANCA and 
FANCE (Fig. S2 D). We also found that FANCL coprecipitated 
with PCNA (Fig. 3 B) and that this interaction was not affected 
by DNaseI treatment (Fig. S2 E), demonstrating that it did not 
depend on DNA.
The FANCL double RING finger/WD repeat 
domain (RWD [DRWD]) domain binds PCNA
We next identified the regions of FANCL that are important for 
binding PCNA. Human FANCL was originally thought to have 
two domains: the N terminus (amino acids 1–306) was predicted to 
Results and discussion
RAD18 and FANCD2 may be  
in a common pathway
Previous studies demonstrated that both RAD18 and FANCD2 
play important roles in eukaryotic cells exposed to cisplatin and 
other DNA cross-linking agents (Yamashita et al., 2002; Nojima 
et al., 2005; Ross et al., 2005; Lee and Myung, 2008; Wagner and 
Karnitz, 2009; Hicks et al., 2010). In our experiments to understand 
the DNA repair pathways that affect the sensitivity of human tumor 
cells to cisplatin, a chemotherapy agent that causes ICL formation 
(Wang and Lippard, 2005), we depleted HeLa cells of FANCD2, 
a key participant in the FA repair pathway, and of RAD18, a regu-
lator of the TLS pathway (Fig. 1 A, inset). As expected, siRNA-
mediated depletion of RAD18 or FANCD2 individually sensitized 
cells to this cross-linking agent (Fig. 1 A and Fig. S1 A), whereas 
only RAD18 depletion sensitized to UV light (Fig. S1 B), which 
creates bulky DNA lesions that are bypassed by TLS polymer-
ases after RAD18-mediated PCNA ubiquitylation (Tateishi et al., 
2000; Kannouche et al., 2004; Watanabe et al., 2004). Surprisingly,   
however, codepletion of both proteins did not cause a more 
profound sensitization to cisplatin. Given that the RAD18 and 
FANCD2 depletions were both highly effective, this result raised 
the possibility that these proteins might act in the same pathway in 
cells treated with agents that cause ICL formation and prompted us 
look further for potential interactions between these pathways.
RAD18 is required for FANCD2 
ubiquitination and chromatin binding
To test for a possible link between RAD18 and FANCD2, we asked 
whether RAD18 depletion affects FANCD2 monoubiquitylation, 
an essential step in the activation of the FA pathway that can be   
assessed by a decreased mobility of FANCD2 on SDS-PAGE. For 
these experiments, we used five independent RAD18 siRNAs: four 
of these siRNAs successfully depleted RAD18, and one caused 
only minimal depletion (Fig. 1 B). Strikingly, all four highly effec-
tive siRNAs reduced cisplatin-induced FANCD2 monoubiquity-
lation in K562 cells. In contrast, the ineffective siRNA did not 
disrupt FANCD2 monoubiquitylation. Similar results were seen in 
HCT-116 RAD18
/ cells (Fig. 1 C) and RAD18-depleted HeLa 
cells (Fig. S1 C). To verify that RAD18 depletion was indeed   
affecting FANCD2 monoubiquitylation, we showed that RAD18 
depletion prevented the addition of transiently expressed HA-
tagged ubiquitin to endogenous FANCD2 (Fig. 1 D). Furthermore, 
we found that RAD18 depletion also blocked the ubiquitylation of 
FANCI (Fig. S1 D) and reduced the cisplatin-induced binding of 
FANCD2 to chromatin, an event that depends on FANCD2 ubiq-
uitylation (Wang et al., 2004), in K562 (Fig. 1 E) and HeLa cells 
(Fig. S1 E). Collectively, these results demonstrate that RAD18 
plays a critical role in the ubiquitylation of ID complex members 
and recruitment of the complex to chromatin after DNA damage.
FANCL and RAD18 appear to function  
in a common pathway
We next explored the relative roles of RAD18 and FANCL in 
FANCD2 monoubiquitylation by depleting RAD18 only, FANCL 
only, or both E3 ligases and examining basal and cisplatin-induced 251 Ubiquitylated PCNA activates FANCL • Geng et al.
contains two separable domains, an E2-like fold (ELF) domain 
and a DRWD domain. To test which FANCL domain is important 
for PCNA binding, we examined binding to the entire N-terminal 
fragment (which contains the ELF and DRWD domains; amino 
acids 1–306), the individual ELF and DRWD domains, and the   
C-terminal RING domain. The N terminus (which contains the 
contain three WD40 domains, and the C terminus (amino acids 
307–375) was predicted to contain a zinc-binding region that is es-
sential for E3 ligase activity (Meetei et al., 2003). However, a very 
recent crystallographic structural analysis of Drosophila melano-
gaster FANCL has further refined our understanding of FANCL’s 
structure (Cole et al., 2010). This study showed that the N terminus 
Figure 1.  RAD18 is required for cisplatin-induced FANCD2 monoubiquitination and recruitment to chromatin. (A) HeLa cells were transfected with   
siRNAs that target Luciferase (Luc), RAD18-1 (R18), FANCD2 (FA-D2), or both. 2 d later, trypsinized cells were analyzed by immunoblotting (inset; note that 
monoubiquitylated FANCD2 is not resolved under these gel conditions) and replated, treated with cisplatin for 24 h, washed, and cultured for 8 d to allow 
colony formation. A representative experiment that has been repeated three times is shown (n = 3 ± SD; see Fig. S1 A for additional replicates). (B) K562 
cells were transfected with siRNAs. 2 d later, the cells were treated with 30 µM cisplatin for 6 h (+), and lysates were immunoblotted. Monoubiquitylated 
FANCD2 (FANCD2
mUb) was detected by slower migration in SDS-PAGE. (C) RAD18
+/+ HCT-116 and RAD18
/ HCT-116 cells were treated with 30 µM 
cisplatin for 6 h and analyzed as in B. (D) K562 cells were cotransfected with siRNAs and plasmids that encode HA-tagged ubiquitin or empty vector 
(EV). 2 d after transfection, the cells were treated as in B. The lysate was immunoprecipitated (IP) with anti-FANCD2 antibody. The immunoprecipitates and 
starting lysates were sequentially immunoblotted to detect HA-ubiquitin covalently linked to FANCD2 (anti-HA mAb) and FANCD2. (E) K562 cells were 
transfected with siRNA, cultured, and treated with cisplatin as in B. Cells were separated into chromatin-bound and soluble fractions, which were analyzed 
by immunoblotting. Western blot markers are given in kilodaltons.JCB • VOLUME 191 • NUMBER 2 • 2010   252
FANCL directly binds PCNA
To further probe the nature of the interaction between PCNA 
and FANCL, we immobilized GST or GST-PCNA on agarose 
beads and incubated the beads with lysates from cells expressing 
SFB-tagged FANCL. Consistent with the immunoprecipitation 
results, GST-PCNA specifically bound to FANCL (Fig. 3 D). 
ELF and DRWD domains) interacted with PCNA, whereas the   
C-terminal RING domain did not (Fig. 3 C). Further subdivision of 
the N terminus into the individual ELF and DRWD domains 
showed that the ELF domain did not bind PCNA, whereas the 
DRWD domain interacted with PCNA, thus demonstrating that the 
DRWD domain is important for the FANCL–PCNA interaction.
Figure  2.  RAD18  participates  in  cisplatin-induced 
FANCD2 monoubiquitylation through the ubiquitylation 
of PCNA on Lys164. (A) K562 cells were transfected 
with siRNAs, cultured for 2 d, and treated with 30 µM 
cisplatin (6 h). Lysates were immunoblotted as indicated. 
*, nonspecific band. (B) HeLa cells were transfected with 
siRNAs. 2 d later, the trypsinized cells were analyzed 
by immunoblotting (Fig. S2 A), and the remaining cells 
were replated, treated with cisplatin for 24 h, washed, 
and cultured for 8 d to allow colony formation. A repre-
sentative experiment of three independent experiments 
is shown (n = 3 ± SD). (C) K562 cells were cotransfected 
twice  with  siRNAs  and  plasmids  that  encode  siRNA-
resistant  wild-type  PCNA  (PCNA
WT)  or  PCNA
K164R.   
2 d after the second transfection, trypsinized cells were 
analyzed by immunoblotting and for cell cycle (Fig. S2 B).   
Short  and  long  exposures  of  the  PCNA  immunoblot 
are shown to demonstrate PCNA loading and PCNA 
monoubiquitylation (PCNA
mUb), respectively. Western blot 
markers are given in kilodaltons.253 Ubiquitylated PCNA activates FANCL • Geng et al.
damage (Matsushita et al., 2005; Alpi et al., 2008), prompted 
us to ask whether PCNA ubiquitylation affected the binding 
of FANCL to chromatin. As shown in Fig. 4 A, the depletion 
of RAD18 profoundly blocked the binding of FANCL to chro-
matin in response to cisplatin. Similarly, in cells expressing   
PCNA
K164R, cisplatin-induced binding of FANCL to chromatin 
was disrupted (Fig. 4 B), confirming that PCNA ubiquitylation 
on Lys164 plays a pivotal role in the recruitment of FANCL   
to chromatin.
Monoubiquitylated PCNA stimulates 
FANCL-catalyzed FANCD2 and  
FANCI ubiquitylation
The known function for PCNA Lys164 monoubiquitylation is to 
recruit and regulate TLS DNA polymerases in a process that re-
quires the ubiquitin-binding domains in the TLS polymerases. 
We therefore initially looked for FANCL domains that could   
interact with ubiquitin; however, despite extended efforts, we were 
unable to find a region of FANCL that stably binds ubiquitin 
To address whether FANCL directly interacted with PCNA, we 
first showed that in vitro–translated full-length FANCL bound 
specifically to PCNA purified from Escherichia coli (Fig. 3 E) 
and then showed that the N-terminal FANCL domain (amino 
acids 1–306), also produced in E. coli, bound PCNA (Fig. 3 F).   
Collectively,  these  results  demonstrate  that  FANCL  directly 
binds PCNA. Moreover, because the bacterially expressed pro-
teins recapitulate the interactions, these results show that this 
interaction does not require the monoubiquitylation of PCNA 
by RAD18.
RAD18 and Lys164 PCNA ubiquitination 
are required for recruitment of FANCL  
to chromatin
The results presented thus far demonstrate two important points. 
First, RAD18-mediated PCNA monoubiquitylation is important 
for FANCD2 ubiquitylation. Second, PCNA binds FANCL, the 
E3 ubiquitin ligase for FANCD2. These observations, coupled 
with the fact that FANCL is recruited to chromatin after DNA 
Figure 3.  FANCL binds PCNA via the FANCL 
DRWD  domain.  (A)  Cell  lysates  from  K562 
cells transiently expressing HA-tagged FANCL 
were  immunoprecipitated  with  nonimmune 
(IgG) or anti-PCNA rabbit antisera. The pre-
cipitates were immunoblotted to detect FANCL 
(anti-HA)  and  PCNA.  (B)  Cell  lysates  from 
K562 cells transfected with empty vector (EV) 
or  transiently  expressing  SFB-tagged  FANCL 
were precipitated with S protein agarose. Pre-
cipitates were immunoblotted to detect PCNA 
and FANCL (anti–S peptide mAb, which rec-
ognizes  the  SFB  tag).  *,  nonspecific  band.   
(C) SFB-tagged versions of the following do-
mains of FANCL were transiently expressed in 
K562 cells: ELF (amino acids 1–103), DRWD 
(amino  acids  104–293),  N  terminus  (amino 
acids 1–306), and RING (amino acids 307–
375).  Cell  lysates  were  immunoprecipitated 
with  nonimmune  or  rabbit  anti-PCNA  anti-
serum, and the precipitates were immunoblot-
ted to detect the SFB tag (anti–S peptide mAb). 
(D and E) GST and GST-PCNA purified from 
E.  coli  were  immobilized  on  GSH  agarose, 
which was incubated with lysates from K562 
cells transiently expressing SFB-FANCL (D) or   
S-tagged FANCL produced by in vitro trans-
lation (E). The washed beads were immuno-
blotted to detect FANCL (anti–S peptide mAb), 
and the membranes were stained with Coo-
massie blue (CB) to show GST and GST-PCNA 
loading. (F) GST and GST-FANCL (amino acids 
1–306)  purified  from  E.  coli  were  immobil-
ized on GSH agarose. Washed beads were 
incubated with E. coli–produced His6-PCNA. 
The precipitates were immunoblotted to detect 
PCNA (anti-PCNA), and the membrane was 
stained with Coomassie blue to show GST and 
GST-FANCL  (amino  acids  1–306)  loading.   
IP, immunoprecipitation. Western blot markers 
are given in kilodaltons.JCB • VOLUME 191 • NUMBER 2 • 2010   254
Figure 4.  Monoubiquitinated PCNA promotes FANCL chromatin binding and stimulates FANCL-mediated FANCD2 and FANCI monoubiquitylation.  
(A and B) K562 cells were cotransfected with siRNAs and plasmids, cultured for 2 d, and treated with 30 µM cisplatin for 6 h. Chromatin-bound and soluble 
fractions were isolated and sequentially immunoblotted to detect FANCL (anti-HA mAb) or the loading controls ORC2 (chromatin-bound fraction) or actin 
(soluble fraction). (C) E. coli–produced GST-PCNA (wild type) and GST-PNCA
K164R were incubated with ubiquitin-activating enzyme E1, RAD18–RAD6 
complex, and HA-ubiquitin (HA-Ub). PCNA preparations (I–III) were repurified by GSH agarose chromatography and analyzed by SDS-PAGE (Coomassie 
Blue stain). (D and E) The repurified PCNA preparations from C were analyzed for effects on FANCL activity. SFB-FANCL alone, SFB-FANCI alone, and 
the combination (D) or SFB-FANCL alone, SFB-FANCD2, and the combination (E) were copurified from K562 cells using S protein agarose. After extensive 
washing, the SFB-tagged proteins were eluted with S peptide and mixed with the indicated E. coli–produced proteins and PCNA preparations (II and III) 
from C under conditions that support in vitro ubiquitylation of FANCI and FANCD2. The reactions were analyzed by sequentially immunoblotting for ubiq-
uitin (anti-HA mAb), FANCL, FANCD2, and FANCI (anti–S peptide mAb). *, nonspecific band. (F) Model of PCNA acting as a central hub in the activation 
of the FA pathway. Western blot markers are given in kilodaltons.255 Ubiquitylated PCNA activates FANCL • Geng et al.
results, taken in conjunction with the recent finding that FANCD2 
has a PCNA interaction motif that is required for DNA damage– 
induced FANCD2 monoubiquitylation (Howlett et al., 2009),   
demonstrate that PCNA also serves as a central hub for the steps 
leading to the activation of the FA pathway in human cells.
Materials and methods
Cell culture, transfections, clonogenic assays, and cell cycle analyses
HeLa and K562 cells obtained from American Type Culture Collection 
were grown and transfected by electroporation as described previously 
(Arlander et al., 2003) and were used 48 or 72 h after transfection as in-
dicated. Cell cycle analyses (Arlander et al., 2003) and clonogenic assays 
(Wagner and Karnitz, 2009) were performed as described previously. 
HCT-116 and HCT-116 RAD18
/ were obtained from T. Shiomi (National 
Institute of Radiological Sciences, Chiba, Japan) and grown as described 
previously (Shiomi et al., 2007).
Materials
Antibodies to the following antigens were used and obtained from the indi-
cated sources: PCNA rabbit polyclonal antisera (provided by J. Chen, M.D. 
Anderson Cancer Center, Houston, TX), PCNA mAb (PC10 mAb; Santa 
Cruz Biotechnology, Inc.), RAD18 (Novus Biologicals), FANCD2 (GeneTex, 
Inc.), FANCA (Bethyl Laboratories, Inc.), FANCE (Bethyl Laboratories, Inc.), 
FANCL (provided by W. Wang, National Institutes of Health, Bethesda, MD), 
ORC2 (BD), -actin (Sigma-Aldrich), HA tag (Covance), S tag (Hackbarth 
et al., 2004), and Flag tag (Flag M1 mAb; Sigma-Aldrich). Micrococcal 
nuclease was obtained from Worthington Biochemical. S protein agarose 
was obtained from EMD. Protein A–Sepharose was obtained from Sigma-
Aldrich. Protein G–Sepharose was obtained from GE Healthcare.
The following duplex siRNAs (Thermo Fisher Scientific) were used: 
RAD18-1,  5-GCUCUCUGAUCGUGAUUUA-3;  RAD18-3,  5-GCAGUU-
UGCUUUAGAGUCA-3; RAD18-4, 5-AUAACCGCAUAUUAGAUGA-3; 
RAD18-5, 5-CCAAGAAACAAGCGUAAUA-3; RAD18-6, 5-GGAGC-
AGGUUAAUGGAUAA-3; luciferase, 5-CUUACGCUGAGUACUUCGA-3 
(Elbashir et al., 2001); FANCD2, 5-GGUCAGAGCUGUAUUAUUC-3 
(Wagner  and  Karnitz,  2009);  PCNA,  5-GGAGAAAGUUUCAGAC-
UAU-3  (Merkerova  et  al.,  2007);  and  FANCL,  5-GACAAGAGCU-
GUAUGCACU-3 (Meetei et al., 2003).
Plasmids
The  FANCL  expression  plasmids  were  created  by  ligating  PCR-amplified   
FANCL into vectors that append an N-terminal SFB tag (pSFB; Chini   
and Chen, 2006), an N-terminal S tag (pSPN; Hackbarth et al., 2004), 
or  a  C-terminal  tandem  HA  tag  (pcDNA3-HA2;  Volkmer  and  Karnitz, 
1999). The S-PCNA expression vector was constructed by ligating PCR-
amplified PCNA into pSPC, which appends a C-terminal S tag (Hackbarth   
et al., 2004). S-PCNA K164R was derived from pSPC-PCNA by site-directed   
mutagenesis. PCNA expression plasmids resistant to the siRNA, four silent 
mutations (identified by underlines), were generated using the oligonucleo-
tide  5-CGCTAGTATTTGAAGCACCAAACCAGGAAAAGGTCTCCGAC-
TATGAAATGAAGTTGATG-3  and  its  reverse  complement  as  primers  for 
site-directed  mutagenesis  reactions  (QuikChange;  Agilent  Technologies). 
The FANCI expression plasmids were constructed by ligating PCR-amplified 
FANCI into pSFB and pcDNA3-HA2 plasmids. The FANCD2 expression vec-
tor (pSFB-FANCD2) used in these experiments encodes amino acids 1–1,394 
of FANCD2. The sequences of all final plasmids were verified to ensure the 
fidelity of all DNA manipulations. The plasmid pET25b-hRAD18-His6hHR6B, 
which was used to express the RAD18–RAD6B complex in E. coli, has 
been described previously (Notenboom et al., 2007) and was provided by   
T. Sixma (Netherlands Cancer Institute, Amsterdam, Netherlands). The GST-
PCNA and GST-FANCL (amino acids 1–306) E. coli expression plasmids 
were generated by ligating PCR-amplified PCNA and FANCL (amino acids 
1–306) into pGEX-KG vector (American Type Culture Collection), respec-
tively. The pET-24a(+)-His6-PCNA plasmid was constructed by ligating a   
PCR-amplified fragment of PCNA into pET-24a(+) vector (EMD).
Cell lysis, cell fractionation, immunoprecipitations, and immunoblotting
For immunoblotting, cells were lysed in SDS-PAGE sample buffer or in 50 mM 
Hepes, pH 7.6, 1% Triton X-100, 10 mM NaF, 30 mM Na4P2O7, 150 mM 
NaCl, 1 mM EDTA supplemented with 10 µg/ml leupeptin, 5 µg/ml pepstatin, 
20 nM microcystin-LR, 5 µg/ml aprotinin, 1 mM Na3VO4, 10 mM 2-glycero-
phosphate, and 10 mM N-ethylmaleimide. The biochemical fractionation of 
(unpublished data). Nonetheless, we reasoned that ubiquityla-
tion of PCNA might affect the activity of FANCL. To test this 
hypothesis, we first set up in vitro PCNA ubiquitylation reactions 
(using the RAD18–RAD6 complex) and produced three PCNA 
preparations (Fig. 4 C): (I) wild-type PCNA incubated with all 
reaction components except ubiquitin, (II) wild-type PCNA   
incubated  with  all  required  components  to  promote  PCNA 
ubiquitylation, and (III) PCNA
K164R, which cannot be ubiquity-
lated because it lacks the ubiquitin acceptor site. These PCNA 
preparations  were  tested  for  their  ability  to  stimulate  the 
FANCL-dependent ubiquitylation of FANCI and FANCD2 
in in vitro reactions. In these reactions, FANCI and FANCD2 
were modestly monoubiquitinated when PCNA
K164R (prepara-
tion III; Fig. 4, D and E, lane 5; and Fig. S3, C and D [uncropped 
image])  or  nonubiquitylated  wild-type  PCNA  (preparation  I; 
Fig. S3, A and B, lane 3) was added to reactions containing all 
other required components. In contrast, monoubiquitylated PCNA 
(preparation II) dramatically stimulated FANCI and FANCD2 
monoubiquitylation (Fig. 4, D and E, lane 4), which was depen-
dent on FANCL and UBE2T (Fig. 4, D and E, lanes 2 and 3). 
Therefore, these results demonstrate that PCNA ubiquitylated   
by RAD18–RAD6 can stimulate the FANCL-mediated mono-
ubiquitylation of FANCD2 and FANCI.
The experiments presented in this study raise several dis-
cussion points. First, our findings differ from experiments in 
chicken DT40 cells, in which codisruption of FANCC, which 
encodes  an  FA  core  complex  member,  and  RAD18  caused 
greater sensitivity to cisplatin than did either individual gene 
disruption alone, suggesting that the FA and RAD18 pathways 
are not epistatic (Hirano et al., 2005). In contrast, our siRNA 
codepletion experiments suggest that the FA and RAD18 path-
ways may be epistatic in terms of cisplatin sensitivity (Fig. 1 A, 
Fig. 2 B, and Fig. S1 A). These disparate findings could reflect 
a difference between human and chicken cells in the regulation 
of the FA. However, it is worth noting that PCNA is still ubiqui-
tylated in RAD18
/ cells and that cells expressing PCNA
K164R 
are more sensitive to cisplatin than are RAD18
/ cells (Simpson 
et al., 2006), thus raising the possibility that the lack of epistasis 
could  be  explained  by  the  residual  PCNA  ubiquitylation  in 
RAD18
/ cells. Alternatively, this discrepancy may stem from 
our use of siRNAs, which, although very effective, do not ablate 
protein expression. Although we cannot definitively determine 
the epistatic relationship of the FA and RAD18 pathways in human 
cells in terms of cisplatin sensitivity, our experiments nonetheless 
clearly demonstrate in multiple human cell models that RAD18 
and monoubiquitylated PCNA are required for FANCD2 ubiqui-
tylation. Future studies that use genetically modified human cells 
will be required to determine whether the interactions between   
human and chicken FA pathways are significantly different.
Second,  these  findings  suggest  the  following  model   
(Fig. 4 F): upon replication fork stalling at cisplatin-induced DNA le-
sions, the RAD18–RAD6 complex ubiquitylates PCNA on Lys164. 
This posttranslationally modified PCNA stimulates activity of the 
PCNA-bound FANCL so that it promotes the monoubiquitylation 
of FANCD2. Although previous studies suggest that ubiquitylated 
PCNA plays an important role in regulating the TLS polymerases 
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soluble and chromatin-bound proteins was performed as described previously 
(Geng et al., 2007). For immunoprecipitations, cells were lysed in 20 mM Tris, 
pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100 supplemented with   
5 mM CaCl2, 300 U/ml micrococcal nuclease, 10 mM N-ethylmaleimide,   
10 µg/ml leupeptin, 5 µg/ml pepstatin, 20 nM microcystin-LR, 5 µg/ml apro-
tinin, 1 mM Na3VO4, and 10 mM 2-glycerophosphate, incubated at 20°C 
for 20 min, and 3 mM EDTA was added. The lysates were centrifuged at 
20,800 g at 4°C for 10 min, and the supernatants were immunoprecipitated. 
All immunoblots were imaged using ECL Western blotting substrate (Thermo 
Fisher Scientific) and exposure to x-ray film. Ratios of ubiquitylated FANCD2 to 
unmodified FANCD2 were determined by scanning and digitizing x-ray films 
using a Gel Doc XR system (Bio-Rad Laboratories) with Quantity One volume 
analysis software (Bio-Rad Laboratories).
GST pull-down assays
GST pull-down experiments were performed as described previously (Bienko 
et al., 2005) using proteins obtained as follows: GST, GST-PCNA, His6-PCNA, 
and GST-FANCL (amino acids 1–306) were purified from E. coli using gluta-
thione agarose (Thermo Fisher Scientific) or TALON Superflow metal affinity 
resin (Takara Bio Inc.) chromatography, S-tagged FANCL was produced with 
a coupled in vitro transcription/translation system (Promega), and SFB-FANCL 
was produced by transient expression in K562 cells.
In vitro ubiquitination assays
To prepare in vitro–ubiquitylated PCNA, 100 ng purified GST-PCNA or   
GST-PCNA
K164R  was  incubated  with  50  ng  rabbit  E1  ubiquitin–activating   
enzyme (EMD) and 350 ng hRAD18-RAD6 (prepared as described previously 
in Notenboom et al. [2007]) with or without 5 µg HA-tagged human ubiquitin 
(Boston Biochem) in ubiquitination reaction buffer (50 mM Tris, pH 7.4, 5 mM 
MgCl2, 2 mM ATP, 2 µM ZnCl2, 2 mM NaF, and 0.6 mM DTT) at 30°C for 1 h. 
The GST-tagged PCNA preparations were incubated with glutathione agarose 
at 4°C for 1 h and washed with 50 mM Tris, pH 7.4, 500 mM NaCl, and 1% 
NP-40 four times and once with ubiquitination reaction buffer.
For the in vitro FANCI and FANCD2 ubiquitylation assays, SFB-
FANCL alone, SFB-FANCI alone, SFB-FANCD2 alone, or indicated combina-
tions were transiently expressed in K562 cells. The cells were lysed in 2.0%   
NP-40, 1 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 420 mM NaCl, and   
soluble proteins were purified using S protein agarose chromatography.   
Precipitates were washed four times in the lysis buffer, once with S peptide   
buffer (20 mM Hepes, pH 7.4, 1% Triton X-100, and 150 mM NaCl), and   
eluted with 1 mg/ml S peptide in S peptide buffer. The purified SFB-tagged   
FANC proteins were mixed with or without 300 ng human recombinant UBE2T 
(Boston Biochem), 50 ng rabbit E1 ubiquitin–activating enzyme, 5 µg HA-tagged 
human ubiquitin (Boston Biochem), and the indicated in vitro–ubiquitinated 
PCNA preparations in ubiquitination reaction buffer, incubated at 30°C for   
1 h, separated by SDS-PAGE, and immunoblotted with anti-HA antibody.
Online supplemental material
Fig. S1 shows that RAD18 is in the same pathway as FANCD2 and is required 
for ID ubiquitylation and chromatin binding. Fig. S2 shows that ubiquitylated 
PCNA and FANCD2 are in the same pathway and that FA pathway compo-
nents interact with PCNA. Fig. S3 shows that ubiquitylated PCNA stimulates 
FANCL-mediated FANCD2 ubiquitylation. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201005101/DC1.
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